NIAID grant supports development of ultra-long-acting HIV integrase inhibitor XVIR-110
Aug. 23, 2023
Exavir Therapeutics Inc. has received a US$3 million award from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health, to support the development of XVIR-110.